Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

What would you like to follow?

Perrigo Company plc (PRGO - Free Report) announced that it has acquired a leading U.S. OTC scar management brand, ScarAway, from Enaltus.

ScarAway is expected to generate revenues of approximately $10 million in 2015 out of which approximately $3 million will be generated for the rest of the year. The transaction is expected to be immediately accretive to earnings.

The company is constantly making acquisitions to expand its business and drive growth. The deal is in line with its 'Base Plus Plus Plus' strategy, focused on the expansion of the company’s durable base business by pursuing selective, accretive transactions.

Last month Perrigo acquired GlaxoSmithKline’s (GSK - Free Report) portfolio of established OTC brands. This transaction is also expected to be immediately accretive to the company’s calendar 2015 adjusted earnings per share. Net sales from the acquired brands in 2014 were approximately $110 million.

We note that earlier this year Perrigo acquired Omega Pharma in a cash-and-equity transaction valued at approximately €3.8 billion. The acquisition has placed Perrigo among the top-five global OTC health care companies by revenue and will allow the company to capture additional share of the $30 billion European OTC market.

Meanwhile, Mylan (MYL - Free Report) is looking to acquire Perrigo. Investor focus is expected to remain on Mylan-Perrigo updates in the near term.

Resources

Client Support

Follow Us

Zacks Mobile App

Zacks Research is Reported On:

Yahoo

MSN

Marketwatch

Nasdaq

Forbes

Investors.com

Morningstar

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25.08% per year. These returns cover a period from January 1, 1988 through March 4, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Visit performance for information about the performance numbers displayed above.

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service.